xCella Biosciences is an integrated oncology drug discovery and development company combining cutting-edge protein engineering technologies with deep biological insights. Our novel antibody discovery platforms (xEmplar™ and xPloration™) unlock and accelerate the development of next-generation therapeutics that harness the innate and adaptive immune systems. Now completing IND‐enabling studies, our lead molecule XC201 is a novel biologic that combines with checkpoint inhibitors and immune modulatory agents to potentiate macrophage and T-cell directed immunotherapy against a wide variety of tumors. Additionally, our synergistic pre‐clinical pipeline of antibodies consists of potent agonists and inhibitors of underexplored and emerging oncology targets. In partnership with leading biopharmaceutical companies, xCella is also pursuing discovery programs against challenging targets and pathways.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
XC201 cancer immunotherapy agent
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):